Biotech Briefs: Ollin, Serapha, Osanni Bio, RQ Bio, Campfield & More
The latest from small and Emerging Pharma companies featuring Campfield Therapeutics, Ollin Biosciences, RQ Bio, Sangamo Therapeutics, Serapha Bio, Boundless Bio, and Vedana Therapeutics.
For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.
* Campfield Raises $180 M for Immune-Mediated Drug Candidates
* Ollin Biosciences Raises $330 M To Support Late-Phase Eye-Disease Drug
* RQ Bio Raises $115 M To Support mAbs for Flu Prevention
* Sangamo Therapeutics Enters Asset-Sale Agreements with Lilly, Astellas
* Serapha Bio, Boundless Bio To Merge; Raise $230 M for Rare Disease Liver Drug
* Vedana Therapeutics Raises $46 M for Migraine Drug Candidates
Campfield Therapeutics Raises $180 M for Immune-Mediated Drug Candidates
Campfield Therapeutics, a San Diego, California-based clinical-stage biopharmaceutical company developimg oral medicines for immune-mediated inflammatory diseases, has launched with $180 million in Series A financing. Initial investors included Novo Holdings.
The company’s lead candidate is prifemilast, a once-daily oral phosphodiesterase 4 (PDE4) inhibitor. The company is initiating a global Phase IIb trial with prifemilast in moderate-to-severe ulcerative colitis and a global Phase II trial in Crohn’s disease. Prifemilast is also being developed in plaque psoriasis in Greater China by Campfield’s partner, Newsoara Biopharma.
Source: Campfield Therapeutics
Ollin Biosciences Raises $330 M for Late-Phase Eye-Disease Drug
Ollin Biosciences, an Austin, Texas-based clinical-stage bio/pharmaceutical company developing treatments for vision-related diseases, has raised $330 million in oversubscribed Series B financing. Proceeds from the financing will support development of OLN324, a bispecific antibody for treating diabetic macular edema and wet age-related macular degeneration, which is expected to enter Phase III development in the second half of 2026. Funding will also support the advancement of OLN102, a bispecific antibody for treating thyroid eye disease and Graves’ disease, which is expected to enter into clinical development this year (2026).
Source: Ollin Biosciences
RQ Bio Raises $115 M for mAbs for Flu Prevention
RQ Bio, a London-based preclinical-stage bio/pharmaceutical company developing long-acting monoclonal antibody (mAb) therapeutics for preventing influenza in high-risk individuals, has raised $115 million from oversubscribed Series A financing.
The company’s lead program, RQB01, currently in investigational new drug-enabling studies, is designed to deliver protection against influenza through a differentiated dual mechanism of action targeting conserved epitopes resilient to seasonal variation.
The company also announced the appointment of biotechnology industry executive Christian S. Schade as Executive Chairman. He most recently served as President and of CEO of Halda Therapeutics, which was acquired by Johnson & Johnson for $3.05 billion in December 2025.
Source: RQ Bio
Sangamo Therapeutics Enters Asset-Sale Agreements with Lilly, Astellas
Sangamo Therapeutics, a genomic medicine company, has entered into two separate asset-sale agreements, one with Eli Lilly and Company for Sangamo’s capsid delivery platform, zinc finger platform, modular integrase platform, and prion disease program, ST-506, and another with Astellas Pharma for its Fabry disease program, isaralgagene civaparvovec. Concurrent with the execution of these asset-sale agreements, Sangamo has commenced voluntary Chapter 11 bankruptcy proceedings in the US.
As part of the sale process, Lilly and Astellas will each serve as “stalking horse bidders” for the sale of the assets contemplated by their respective agreements. A stalking horse asset sale agreement establishes a baseline offer and is intended to help maximize value for all stakeholders through the Chapter 11 auction process. Certain other company assets, including the clinical-stage ST-503 program to treat chronic neuropathic pain, the giroctocogene fitelparvovec program to treat hemophilia A, and Sangamo’s cell therapy and regulatory T cell assets, are not included in either stalking horse bid, and are also expected to remain available to interested bidders at the auction.
Source: Sangamo Therapeutics
Serapha Bio, Boundless Bio To Merge; Raise $230 M for Rare Disease Liver Drug
Boundless Bio, a San Diego, California-based clinical-stage bio/pharmaceutical company, and Serapha Bio, a New York-based clinical -stage pharmaceutical company developing an investigational in vivo base editing therapy for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic liver disease, have agreed to merge in an all-stock transaction. In support of the proposed merger, Serapha has secured commitments for pre-closing private investments of approximately $230 million from a syndicate of investors.
Serapha Bio’s lead candidate is SERP-01 developed in Greater China by Shanghai-based YolTech Therapeutics and licensed to Serapha in exchange for an upfront cash payment and a minority equity stake in Serapha. YolTech is also eligible to receive regulatory and commercial milestones totaling over $2 billion and tiered royalties on net sales of SERP-01. YolTech has been enrolling AATD patients in an investigator-initiated trial in China and retains development and commercialization rights for the Greater China territory.
Prior to the closing, Boundless Bio expects to declare a cash dividend to pre-merger Boundless stockholders. Upon completion of the transaction, the combined company plans to operate under the name Serapha Bio. The transaction has received unanimous approval by the Board of Directors of both companies and is expected to close in the fourth quarter of 2026, subject to certain closing conditions, including, among others, approval by the stockholders of each company, and other conditions.
Source: Serapha Bio
Vedana Therapeutics Raises $46 M for Migraine Drug Candidates
Vedana Therapeutics, a Seattle, Washingon preclinical bio/pharmaceutical company developing therapies for migraine prevention, has launched with $46 million in Series A financing.
The company is developing a portfolio of long-acting subcutaneously dosed monoclonal antibodies targeting the pituitary adenylate cyclase-activating polypeptide drug class. Its first drug candidates are expected to enter the clinic in first-in-human studies in 2027.
Source: Vedana Therapeutics
